ArticleLeukemia2020
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination.
Abstract read
In one paragraph
Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Phenotypic evolution of circulating plasma cells from early precursor stages to multiple myeloma.Haematologica · 2026Article
- Article
- Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma.British journal of haematology · 2026Review
- Distinct immunophenotypic profiles of circulating tumor plasma cells in MGUS and smoldering multiple myeloma.International journal of hematology · 2026Article
- Enhanced Detection of Multiple Myeloma Cells by Next-Generation Flow Cytometry Following Density Gradient Medium Separation.European journal of haematology · 2026Article
- Article
- Myeloid-derived suppressor cells in multiple myeloma: mechanistic insights and therapeutic implications.Frontiers in immunology · 2026Review
- Circulating tumor cells in breast cancer bone metastasis: mechanisms, clinical relevance, and future directions.Cell death discovery · 2025Review
- Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma.HemaSphere · 2025Article
- SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors.Nature cancer · 2025Article
- Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma.Nature reviews. Clinical oncology · 2025Review
- Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.BMC medical genomics · 2025Article
- PNPO-Mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and Osteoclastogenesis by Activating the Wnt/β-Catenin Pathway.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A review on pathobiology of circulating tumour plasma cells: The sine qua non of poor prognosis in plasma cell neoplasms.Oncology research · 2025Review
- Article
- Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors.Leukemia · 2024Article
- Liquid Biopsies as Non-Invasive Tools for Mutation Profiling in Multiple Myeloma: Application Potential, Challenges, and Opportunities.International journal of molecular sciences · 2024Review
- Review
- Liquid biopsy by analysis of circulating myeloma cells and cell-free nucleic acids: a novel noninvasive approach of disease evaluation in multiple myeloma.Biomarker research · 2023Review
- More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Juan-Jose Garcés *Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain.ORCID http://orcid.org/0000-0001-9235-4671
Michal Simicek *Department of Hematooncology, University Hospital of Ostrava, Ostrava, Czech Republic.
Marco VicariCampus Bio-Medico University of Rome, Rome, Italy.
Lucie BrozovaMasaryk University, Brno, Czech Republic.
Leire BurgosClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
Renata BezdekovaUniversity Hospital Brno, Brno, Czech Republic.
Diego AlignaniClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
Maria-Jose CalasanzClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
Katerina GrowkovaDepartment of Hematooncology, University Hospital of Ostrava, Ostrava, Czech Republic.
Ibai GoicoecheaClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
Xabier AgirreClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
Ludek PourUniversity Hospital Brno, Brno, Czech Republic.
Felipe ProsperClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain.ORCID http://orcid.org/0000-0001-6115-8790
Rafael RiosHospital Universitario Virgen de las Nieves, Granada, Spain.
Joaquin Martinez-LopezHospital Universitario 12 de Octubre, Madrid, Spain.
Pamela MillacoyComplejo Hospitalario de Navarra, Pamplona, Spain.
Luis PalomeraHospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
Rafael Del OrbeBiocruces Health Research Institute, Barakaldo, Spain.ORCID http://orcid.org/0000-0002-1240-1958
Albert Perez-MontañaHospital Son Espases, Palma, Spain.
Sonia GarateClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
Laura BlancoClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
Marta LasaClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
Patricia MaisoClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
Juan Flores-MonteroCancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca (USAL), , CIBER-ONC number CB16/12/00400, Salamanca, Spain.
Luzalba Sanoja-FloresCancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca (USAL), , CIBER-ONC number CB16/12/00400, Salamanca, Spain.
Zuzana ChyraDepartment of Hematooncology, University Hospital of Ostrava, Ostrava, Czech Republic.
Alexander VdovinDepartment of Hematooncology, University Hospital of Ostrava, Ostrava, Czech Republic.
Tereza SevcikovaDepartment of Hematooncology, University Hospital of Ostrava, Ostrava, Czech Republic.
Tomas JelinekDepartment of Hematooncology, University Hospital of Ostrava, Ostrava, Czech Republic.
Cirino BottaDepartment of Clinical and Experimental Medicine, Magna Graecia University, Catanzaro, Italy.ORCID http://orcid.org/0000-0002-1522-4504
Halima El OmriNational Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Jonathan KeatsTranslational Genomics Research Institute, Phoenix, AZ, USA.ORCID http://orcid.org/0000-0003-4375-7399
Alberto OrfaoCancer Research Center (IBMCC-CSIC/USAL-IBSAL), Cytometry Service (NUCLEUS) and Department of Medicine, University of Salamanca (USAL), , CIBER-ONC number CB16/12/00400, Salamanca, Spain.
Roman HajekDepartment of Hematooncology, University Hospital of Ostrava, Ostrava, Czech Republic.
Jesus F San-MiguelClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
Bruno PaivaClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain. bpaiva@unav.es.
Funding
Cancer Research UK
Abstract
The reason why a few myeloma cells egress from the bone marrow (BM) into peripheral blood (PB) remains unknown. Here, we investigated molecular hallmarks of circulating tumor cells (CTCs) to identify the events leading to myeloma trafficking into the bloodstream. After using next-generation flow to isolate matched CTCs and BM tumor cells from 32 patients, we found high correlation in gene expression at single-cell and bulk levels (r ≥ 0.94, P = 10
Indexed as
Bone MarrowCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionGene ExpressionHumansHypoxiaInflammationMultiple MyelomaNeoplastic Cells, CirculatingNeoplastic Stem CellsPrognosisTranscription, GeneticTumor Microenvironment
Identifiers
PMID
31595039What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.